arrow
Return

Long-term risk of death in patients with hidradenitis suppurativa

delete2022-09-13
delete6
PRE
AI
J
John J. Kohorst
S
Shirin Ghanavatian
M
Mark D.P. Davis
A
Amy L. Weaver
C
Cathy D. Schleck
S
Swanson, David L. *
DOI:10.1111/ijd.16409delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
Background Hidradenitis suppurativa (HS) is associated with substantial morbidity. Few studies have addressed the natural history and mortality rates associated with HS. A higher risk of cardiovascular death in patients with HS has been reported. We investigated whether patients with HS have an increased overall risk of death compared with age- and gender-matched referents. Methods We performed a retrospective cohort study of residents of Olmsted County, Minnesota, with incident HS between January 1, 1980, and December 31, 2008, and age- and gender-matched referents. The main outcomes and measures were the overall and cause-specific risks of death. Results We identified 226 incident cases of HS and 678 age- and gender-matched referents among Olmsted County residents during the study period. Compared to referents, patients with HS had a significantly higher risk of all-cause death (hazard ratio [HR, 2.48; 95% CI, 1.53-4.03, P < 0.001) and cardiovascular- or cerebrovascular-related death (HR, 2.85; 95% CI, 1.10-7.40, P = 0.03). However, these risks were attenuated by adjusting for smoking history: all-cause HR, 1.65 (95% CI, 0.97-2.82, P = 0.07) and cardiovascular- or cerebrovascular-related HR, 2.03 (95% CI, 0.71-5.81, P = 0.18). The 71% of patients were former or current smokers at the time of HS diagnosis. Conclusions Hidradenitis suppurativa patients have a substantially increased risk of death from any cause, including cardiovascular or cerebrovascular causes; the risk is especially dependent on smoking history.
Keywords:
MEDICAL-RECORDS LINKAGE
QUALITY-OF-LIFE
POPULATION
PREVALENCE
SKIN

Journal

International Journal of Dermatology cover
International Journal of Dermatology
IF:
3.2
Papers:
1.2W
Citations:
1.0W

Organization

M
mayo clinic
Scholars:
8.1W
Papers: 6.5W
Citations: 85
M
mayo clinic phoenix
Scholars:
6.9K
Papers: 5.5K
Citations: 4